What does the licensing of teplizumab mean for diabetes care?
Saved in:
| Title: | What does the licensing of teplizumab mean for diabetes care? |
|---|---|
| Authors: | Quinn LM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Swaby R; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Tatovic D; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Narendran P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.; Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK., Besser REJ; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Paediatrics, National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK., Dayan CM; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Aug; Vol. 25 (8), pp. 2051-2057. Date of Electronic Publication: 2023 Apr 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.15071 |
